Probatebeta
Target

DRD1

Dopamine receptor D1

As of the edition of 20 October 2026, DRD1 (dopamine receptor D1, UniProt P21728) has 15 drugs tested at it and 14 companies on the list, 1 on route A and 3 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P21728
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
35
Disease areas
Nervous system; Mental health; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Chemically induced; Nutrition and metabolism; Digestive system
Registered trials of its drugs
102

Drugs at this target

StatusCount
Marketed7
Active2
Went quiet1
Stopped2
Withdrawn from market3
Total15
DrugStatusFurthest phaseUS protection
EcopipamActivePhase 3none listed
TavapadonStoppedPhase 3none listed
FlupentixolMarketedPhase 4none listed
FenoldopamMarketedPhase 4none listed
PergolideWithdrawn from marketPhase 4none listed
MevidalenActivePhase 2none listed
PimozideMarketedPhase 4none listed
MethylergonovineMarketedPhase 4none listed
DihydrexidineWent quietPhase 2none listed
RazpipadonStoppedPhase 2none listed
ZuclopenthixolMarketedPhase 4none listed
ErgoloidMarketedPhase 2none listed

12 of 15 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B3
Engaged4
Undetermined6
Total on the list14
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Bausch HealthRoute A
LundbeckRoute B

The other 11 companies at DRD1

In the product

14 companies in all; 11 are not named here, and no score is.

See the 14 companies at DRD1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at DRD1

Other targets in nervous system

Companies holding approvals at DRD1